Marita Mariotti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/123609/publications.pdf

Version: 2024-02-01

1478505 1720034 7 382 6 7 citations h-index g-index papers 8 8 8 934 citing authors docs citations times ranked all docs

| # | Article | IF | CITATIONS |
|---|--|-----|-----------|
| 1 | The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives. Critical Reviews in Oncology/Hematology, 2021, 157, 103199. | 4.4 | 16 |
| 2 | Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer. Journal of Clinical Medicine, 2019, 8, 131. | 2.4 | 42 |
| 3 | Frequency of actionable alterations in epidermal growth factor receptor (EGFR) wild type non-small cell lung cancer: experience of the Wide Catchment Area of Romagna (AVR). Journal of Thoracic Disease, 2018, 10, 4858-4864. | 1.4 | 2 |
| 4 | Impact of <i>TP53</i> Mutations on Outcome in <i>EGFR</i> -Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors. Clinical Cancer Research, 2017, 23, 2195-2202. | 7.0 | 208 |
| 5 | Paraneoplastic lipase and amylase production in a patient with small-cell lung cancer: case report. BMC Cancer, 2016, 16, 118. | 2.6 | 9 |
| 6 | Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy. Clinical Lung Cancer, 2016, 17, 384-390. | 2.6 | 77 |
| 7 | Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?. International Journal of Molecular Sciences, 2015, 16, 747-757. | 4.1 | 28 |